Fig. 4: Line plot of mean change in CSFT from baseline by visit up to Week 64. | Eye

Fig. 4: Line plot of mean change in CSFT from baseline by visit up to Week 64.

From: TALON phase IIIb study: 64 week results of brolucizumab versus aflibercept using treat-and-extend for neovascular age-related macular degeneration

Fig. 4: Line plot of mean change in CSFT from baseline by visit up to Week 64.

Secondary endpoint. ANOVA Analysis of variance, CI confidence interval, CSFT central subfield thickness, LOCF last observation carried forward, LS least squares, SE standard error. ANOVA baseline CSFT categories (<400 μm, ≥400 μm), age categories (<75 years, ≥75 years) and treatment as fixed effects. If Week 28/60 CSFT value is not available, Week 30/62 CSFT is used, otherwise LOCF is used.

Back to article page